Table I.
Association between MPC protein expression in tumor tissue and clinicopathological parameters in hepatocellular carcinoma patients.
| MPC1 | MPC2 | |||||
|---|---|---|---|---|---|---|
| Clinical characteristics | High (n=43) | Low (n=42) | P-value | High (n=42) | Low (n=43) | P-value |
| Age, year | 54.8±9.5 | 54.7±11.2 | 0.426 | 55.7±10.9 | 53.9±9.8 | 0.386 |
| Gender (male/female) | 33/10 | 37/5 | 0.255 | 33/9 | 37/6 | 0.407 |
| ALT (U/l) | 37.4±25.5 | 37.0±19.0 | 0.131 | 34.1±21.7 | 37.2±23.1 | 0.626 |
| AST (U/l) | 40.6±27.1 | 37.6±27.0 | 0.864 | 39.5±32.1 | 37.8±21.4 | 0.507 |
| TBIL (µmol/l) | 17.0±10.0 | 19.6±12.9 | 0.999 | 19.6±14.2 | 17.2±8.2 | 0.120 |
| ALB (g/l) | 46.3±4.1 | 43.5±6.6 | 0.187 | 44.0±6.6 | 45.8±4.4 | 0.431 |
| PT, sec | 11.2±1.1 | 11.8±3.1 | 0.296 | 11.7±3.2 | 11.4±1.2 | 0.441 |
| PLT, ×109/l | 158.0±69.8 | 167.9±48.9 | 0.473 | 162.6±80.4 | 163.6±69.1 | 0.411 |
| AFP (>200/≤200 ng/ml) | 16/27 | 15/27 | 1.000 | 17/25 | 14/29 | 0.504 |
| BCLC Stage (0-A/B-C) | 23/20 | 15/27 | 0.128 | 18/24 | 20/23 | 0.828 |
| Tumor number (1/>1) | 35/8 | 39/3 | 0.195 | 36/6 | 38/5 | 0.757 |
| Tumor size | ||||||
| Maximum diameter (>5/≤5 cm) | 16/27 | 21/21 | 0.278 | 20/22 | 17/26 | 0.515 |
| Smallest diameter (>3/≤3 cm) | 19/24 | 24/18 | 0.281 | 22/20 | 21/22 | 0.829 |
| Differentiation (poor/moderate or well) | 16/27 | 13/29 | 0.649 | 14/28 | 15/28 | 0.880 |
| Microvascular invasion (yes/no) | 23/20 | 25/17 | 0.663 | 23/19 | 25/18 | 0.828 |
| Micrometastases (yes/no) | 14/29 | 18/24 | 0.375 | 17/26 | 16/27 | 0.824 |
Data are presented as mean ± standard deviation or n. MPC, mitochondrial pyruvate carrier; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; PT, prothrombin time; PLT, platelet; AFP, α-fetoprotein.